Status:
UNKNOWN
Value of CD26 Positive Leukemic Stem Cell in Myeloproliferative Neoplasm
Lead Sponsor:
Safaa AA Khaled
Conditions:
Myeloproliferative Neoplasm
Eligibility:
All Genders
18+ years
Brief Summary
Evaluate diagnostic and prognostic value of CD26 positive stem cell Stem Cells in classic myeloproliferative neoplasms (MPNs). To study CD26 expression on different phases of CML (chronic phase, acce...
Detailed Description
Classic Myeloproliferative neoplasms (MPNs) are a heterogeneous group of diseases including Chronic myeloid leukemia (CML), polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofib...
Eligibility Criteria
Inclusion
- Patients diagnosed one of classic MPNs (CML, PV, ET, PMF).
Exclusion
- Patients below 18 years.
- Pregnancy.
- Any associated Solid or hematopoietic neoplasm.
Key Trial Info
Start Date :
August 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 1 2022
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT04312607
Start Date
August 1 2020
End Date
March 1 2022
Last Update
March 18 2020
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.